November, 1989: The first RCTsDiBisceglie, et al., N Engl J Med; 321: 1506-10.

Study Validity:

• Strengths

- Well designed; adequate blindedness; ITT analysis.

• Weaknesses

- Small size.

- 10% HCV Ab negative.

- ᡌ% with prior HBV exposure.

- Significantly lower pre-treatment ALTs in IFN group.

- Placebo data not stated; unable to calculate NNT.

- ? Clinical importance of endpoints.

- Supported by Schering-Plough.

Previous slide

Next slide

Back to first slide

View graphic version